We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 11-20 of 251

Final injunction permits existing patients to continue to receive infringing medicine

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • June 10 2014

This decision relates to the crafting of a final injunction for the sale of STELARA following a finding of infringement. In an earlier trial decision

Patent infringement action dismissed since no claims were both valid and infringed

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • June 2 2014

This was a patent infringement action, relating to an invention that pertains to the general field of building construction. The Court conducted a

Experts permitted to attend testing at plaintiff's facility

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • June 2 2014

This Order was issued in 2012, but just made public now. The defendant brought a motion seeking to permit its experts to attend testing, for samples

PMPRB not found to have jurisdiction over two generic companies in separate decisions

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • June 2 2014

In the first of two similar decisions, the Federal Court has found that Sandoz Canada is not under the jurisdiction of the PMPRB because Sandoz does

Prohibition granted re the compound patent; dismissed re use and polymorph patents

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • May 30 2014

This NOC proceeding deals with challenges to three patents, a compound patent, a use patent and a polymorph patent

Product specificity is the same for different types of claims in listing on the Patent Register

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • May 30 2014

Teva brought a motion pursuant to section 6(5)(a) of the Patented Medicines (Notice of Compliance) Regulations relating to the listing of a patent on

Court bifurcates determination of Start Date for section 8 action

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • May 30 2014

This is an action commenced pursuant to section 8 of the Patented Medicines (Notice of Compliance) Regulations. Pfizer counterclaimed against Apotex

Oder of prohibition issues no promise to treatment in humans or reduced side effects was found

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • April 30 2014

Pfizer’s Canadian Patent No. 2,177,576 for Celebrex has withstood Apotex’s allegations and was found to be valid; therefore the Minister is

Other industry news

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • April 30 2014

The PMPRB has published a new analytical report: Utilization of Prescription Opioids in Canada's Public Drug Plans, 200607 to 201213

Supreme Court denies Apotex leave to appeal; prohibition order stands

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • April 30 2014

The Supreme Court of Canada (SCC) denied Apotex leave to Appeal the decision of the Federal Court of Appeal (FCA) in a s. 8 case (decision here